Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. 2014

Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
Faculty of Chemistry, Institute of Analytical Chemistry, University of Vienna , Währingerstraße 38, A-1090 Vienna, Austria.

The pathogenesis of multiple myeloma (MM) is regarded as a multistep process, in which an asymptomatic stage of monoclonal gammopathy of undetermined significance (MGUS) precedes virtually all cases of MM. Molecular events characteristic for the transition from MGUS to MM are still poorly defined. We hypothesized that fibroblast-like cells in the tumor microenvironment are critically involved in the pathogenesis of MM. Therefore, we performed a comparative proteome profiling study, analyzing primary human fibroblast-like cells isolated from the bone marrow of MM, of MGUS, as well as of non-neoplastic control patients. Thereby, a group of extracellular matrix (ECM) proteins, ECM receptors, and ECM-modulating enzymes turned out to be progressively up-regulated in MGUS and MM. These proteins include laminin α4, lysyl-hydroxylase 2, prolyl 4-hydroxylase 1, nidogen-2, integrin α5β5, c-type mannose receptor 2, PAI-1, basigin, and MMP-2, in addition to PDGF-receptor β and the growth factor periostin, which are likewise involved in ECM activities. Our results indicate that ECM remodeling by fibroblast-like cells may take place already at the level of MGUS and may become even more pronounced in MM. The identified proteins which indicate the stepwise progression from MGUS to MM may offer new tools for therapeutic strategies.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D005109 Extracellular Matrix A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. Matrix, Extracellular,Extracellular Matrices,Matrices, Extracellular
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
November 2017, Leukemia,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
September 2007, Journal of clinical pathology,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
September 2014, Oncotarget,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
August 2017, Cancer immunology, immunotherapy : CII,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
January 2012, Journal of biomedicine & biotechnology,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
July 1994, British journal of haematology,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
January 2011, American journal of blood research,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
May 2023, World journal of stem cells,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
January 2001, Circulation research,
Astrid Slany, and Verena Haudek-Prinz, and Anastasia Meshcheryakova, and Andrea Bileck, and Wolfgang Lamm, and Christoph Zielinski, and Christopher Gerner, and Johannes Drach
October 2002, International journal of cancer,
Copied contents to your clipboard!